FY2029 Earnings Estimate for FULC Issued By HC Wainwright

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Fulcrum Therapeutics in a research note issued on Wednesday, February 26th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.95) per share for the year. HC Wainwright currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Price Performance

Shares of FULC opened at $3.37 on Thursday. The firm has a market cap of $181.77 million, a P/E ratio of -10.87 and a beta of 2.03. Fulcrum Therapeutics has a 1 year low of $2.86 and a 1 year high of $13.70. The stock has a 50 day simple moving average of $4.12 and a two-hundred day simple moving average of $4.61.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03).

Institutional Trading of Fulcrum Therapeutics

A number of institutional investors have recently modified their holdings of FULC. BNP Paribas Financial Markets purchased a new position in shares of Fulcrum Therapeutics during the fourth quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. lifted its position in Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after buying an additional 4,701 shares during the period. Mariner LLC bought a new stake in Fulcrum Therapeutics during the fourth quarter worth about $78,000. Walleye Capital LLC bought a new stake in shares of Fulcrum Therapeutics in the 3rd quarter worth approximately $59,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Fulcrum Therapeutics in the third quarter worth $62,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.